Table 1.
NOD/SCID-based immunocompromised mice.
| Mice | NOD/SCID | NOG | NSG | NOJ |
|---|---|---|---|---|
| Strain | NOD.Cg-Prkdcscid | NOD.Cg-PrkdcscidIl2rgtm1Sug/Jic | NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ | NOD.Cg-PrkdcscidJak3tm1card |
| Genetic defects | SCID | SCID, IL-2γ Partial deficiency | SCID, IL-2Rγ Complete deficiency | SCID, Jak3 deficiency |
| Developer | CIEA 1, Jackson Laboratory |
CIEA 1 | Jackson Laboratory | Kumamoto University |
| Supplier | Japan Clea Charles River |
Japan Clea | Charles River | Kumamoto University |
| NK activities | NK cell dysfunction | Complete loss of NK cells | Complete loss of NK cells | Complete loss of NK cells |
| Reference | [18] | [21] | [22] | [23] |
1 Central Institute for Experimental Animals (CIEA). NOD = non-obese diabetic; SCID = severe combined immunodeficient; NOG = NOD/SCID/IL-2 receptor γ-deficient (IL2Rγnul); NSG = NOD/SCID/IL2Rγnul; NOJ = NOD/SCID/Janus kinase 3 deficient (Jak3); Prkdc = protein kinase, DNA activated, catalytic polypeptide; NK = natural killer.